Ralph Kern
Institution Name:
BrainStorm Cell Therapeutics
Total Awards:
1
Award Value:
$15,912,390
Awards as PI
Program Type | Institution | Grant Title | Award Value |
---|---|---|---|
Clinical Trial Stage Projects | BrainStorm Cell Therapeutics | A Phase 3, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy & Safety of Repeated Administrations of NurOwn® in Patients with ALS | $15,912,390 |
Total: $15,912,390.00 |
Publications
- Muscle Nerve 2022 A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. (PubMed: 34890069)
- Muscle Nerve 2022 Erratum. (PubMed: 35960989)